Form 8-K - Current report:
SEC Accession No. 0001628280-26-044618
Filing Date
2026-06-22
Accepted
2026-06-22 16:05:46
Documents
14
Period of Report
2026-06-18
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K allo-20260618.htm   iXBRL 8-K 51460
2 EX-3.1 exhibit31toform2026annualm.htm EX-3.1 11356
3 EX-5.1 exhibit51toformjune2026pro.htm EX-5.1 17195
7 image_1a.jpg GRAPHIC 11997
  Complete submission text file 0001628280-26-044618.txt   221154

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20260618.xsd EX-101.SCH 1870
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20260618_lab.xml EX-101.LAB 21885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20260618_pre.xml EX-101.PRE 12595
17 EXTRACTED XBRL INSTANCE DOCUMENT allo-20260618_htm.xml XML 2763
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 261107031
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)